(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
----------
AIM - WINNERS
----------
Pantheon Resources PLC, up 17% at 60.64 pence, 12-month range 17p-63.40p. The oil & gas exploration and development company completes its internal analysis of the SMD-B sequence encountered in the Talitha #A well, located on the Alaska North Slope. The SMD is the shallowest of five discrete oil bearing intervals encountered in that well. The data obtained in Talitha #A has allowed Pantheon to integrate well log response and core data with seismic petrophysics to more accurately map this interval. Pantheon says analysis of the SMD-B zone is estimated to show that this zone has the potential to contain 2.6 billion barrels oil in place and a P50 contingent resource of 404 million barrels of recoverable oil. This compares to 1.8 billion barrels of oil in place and 484 million barrels of contingent resource across all three zones previously. Pantheon also said it is in discussions for farmouts of a percentage of one or more Alaskan projects.
----------
ImmuPharma PLC, up 6.4% at 8.77p, 12-month range 7.63p-17.10p. The biopharmaceutical company names Tim Franklin as chief operating officer. Franklin has worked with ImmuPharma for over three years, initially as a consultant. His key responsibilities include working closely with ImmuPharma's clinical team and scientific advisors, as the company looks to further progress its wider drug development portfolio, both through clinical development and partnering opportunities.
----------
Hutchmed (China) Ltd, up 5.2% at 572.00p, 12-month range 337p-656p. The biopharmaceutical company says the European Medicines Agency has passed its marketing authorization application for surufatinib, a treatment for pancreatic and extra-pancreatic neuroendocrine tumours. Adds the agency's validation confirms that the submission is ready for formal review.
----------
SigmaRoc, up 3.3% at 92.41p, 12-month range 37.20p-101p. The building materials company raises GBP260 million, before expenses, via the issue of 305.9 million new shares at a price of 85 pence each. The gross proceeds from the placing will be used to satisfy the EUR270 million cash element of the EUR470 million due pursuant to the acquisition of Nordkalk. Meanwhile, the retail offer has raised additional gross proceeds of GBP1.6 million at the placing price for the company, via the subscription for 1.9 million new shares, which will be used for general working capital purposes.
----------
AIM - LOSERS
----------
eve Sleep PLC, down 16% at 3.88p, 12-month range 1.30p-9.50p. The direct-to-consumer mattress retailer says UK & Ireland market had "good" first half. Expects group revenue in six months to June 30 of GBP13.9 million, up 13% year on year. UK & Ireland revenue surged 18%, but notes French revenue down 8%, attributed to "minimal" marketing investment in the first quarter ahead of a new TV campaign, which was launched in May. Notes that versus pre-pandemic revenue in the first half of 2019, UK & Ireland sales were 15% higher.
----------
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)
Immupharma (IMM)
Sigmaroc. (SRC)
Pantheon Res (PANR)